GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

NCT07554859 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: ArmA:GFH375
DRUG: Arm B:GFH375
DRUG: Arm C:GFH375

Sponsor

Genfleet Therapeutics (Shanghai) Inc.